Exploring the impact of durvalumab on biliary tract cancer
...insights from real-world clinical data
Recent publication
In a recent study, researchers investigated the effectiveness of durvalumab, an immunotherapy drug, in combination with platinum and gemcitabine for the treatment of bile duct cancer (biliary tract carcinoma, BTC). Based on the results of the TOPAZ-1 study, they were able to show that the combination is effective in practice and can improve both the time to disease progression and the survival time of patients. Hossein Taghizadeh, a researcher at the KL, was part of the team of authors. The study was published open access in the journal ‘Cancer Immunology, Immunotherapy’.
Reimann, P., Mavroeidi, IA., Burghofer, J. et al. Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data. Cancer Immunol Immunother 73, 251 (2024). https://doi.org/10.1007/s00262-024-03842-y
OA PD Dr. Hossein Taghizadeh MSc PhD
Division of Internal Medicine 1 (University Hospital St. Pölten)
More about Dr Hossein Taghizadeh MSc PhD
Hossein Taghizadeh, Oncologist
First-class research raises the profile of our clinic as a centre of oncological excellence